ADVA
1.9.2020 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Colocation Australia (ColoAU), a subsidiary of 5G Networks Limited (ASX: 5GN), has deployed its FSP 3000 OpenFabric™ to give customers flexible and low-cost connectivity with complete freedom to adjust capacity as required. The company’s new national wavelength product uses bandwidth sourced from a range of providers to offer cost-effective long-distance transport. By using ADVA’s open OTN cross-connect technology, ColoAU is now able to optimize links between Australia’s mainland state capital cities and Singapore to offer the lower-speed services that businesses need. Customers can select data rates ranging from 1.25Gbit/s to 50Gbit/s over OTN, Ethernet, SDH/SONET and Fibre Channel interfaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005020/en/
“We’re using ADVA’s technology to solve one of the key problems that small and medium-sized companies face. They no longer need to waste valuable resources in overprovisioning links that end up redundant or obsolete and are able to support growing bandwidth requirements driven by demand. By utilizing the ADVA FSP 3000 OpenFabric™, we’re able to provide elastic bandwidth offerings that can instantly be turned up or down,” said Nic Tippelt, wholesale manager, ColoAU. “Our new national wavelength product lets customers take control. It empowers them to choose high-quality, secure, point-to-point connectivity that supports ever-changing capacity needs.”
The ADVA FSP 3000 OpenFabric™ gives ColoAU and 5GN Wholesale a truly scalable end-to-end architecture and the ability to support a wide range of client interfaces for metro, inter-capital or international connectivity. It enables the company to leverage other service provider and utility networks as its own and offer a unique combination of high capacity and flexibility. The ADVA FSP 3000 OpenFabric™ features open OTN switching technology , which extends the delivery of bandwidth services throughout the network and eliminates the boundaries of legacy OTN solutions. With the new service, ColoAU has become the first company to use the openness, flexibility and scalability of ADVA’s solution in this way.
“Our FSP 3000 OpenFabric™ creates an architecture that’s open, disaggregated and completely future-proof. It gives ColoAU’s customers the freedom to efficiently transport any mix of optical services, and scale as and when needed. By utilizing other networks to flexibly offer a wide range of wavelengths, the company is empowering enterprises across Australia to harness the ideal connectivity for their business needs,” commented Erik Lindberg, VP, sales, APAC, ADVA. “ColoAU’s new national wavelength product provides businesses across Australia and Singapore with an entirely new way to access the capacity they require. It enables them to seize new opportunities without major risk and eliminates wasted capacity and unnecessary cost.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About 5G Networks and Colocation Australia
Colocation Australia is a subsidiary company of 5G Networks. 5G Networks (ASX: 5GN) is a licenced telecommunications carrier operating across Australia. Our mission is to be Australia’s partner of choice for unifying a seamless digital experience for our customers across data connectivity, cloud and data centre services, underpinned by expert managed services in the business and wholesale markets. 5G Networks currently owns and operates its own nationwide highspeed data network with points of presence in all major Australian capital cities. www.5gnetworks.com.au .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005020/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom